
FDA approves UCB's ZILBRYSQ autoinjector for generalized myasthenia gravis, offering a new once-daily self-administration option.
You can purchase shares of UCB SA UNSP/ADR by UCB S.A. (OTCPK:UCBJY) through any online brokerage.
There are no as such competitors for UCB SA UNSP/ADR by UCB S.A..
There is no analysis for UCB SA UNSP/ADR by UCB S.A. to provide a consensus price target.
The stock price for UCB SA UNSP/ADR by UCB S.A. (OTCPK: UCBJY) is $150.39 last updated October 26, 2026 at 3:16 PM EDT.
There are no upcoming dividends for UCB SA UNSP/ADR by UCB S.A..
UCB SA UNSP/ADR by UCB S.A. does not have any upcoming earnings scheduled.
There is no upcoming split for UCB SA UNSP/ADR by UCB S.A..
UCB SA UNSP/ADR by UCB S.A. is in the Health Care sector and Pharmaceuticals industry. They are listed on the OTCPK.
UCB is a Belgium-based biopharma firm focused on the development of novel therapies for the treatment of central nervous system and immunologic diseases. Historically, revenue was derived from allergy medicine Zyrtec and epilepsy drug Keppra, which...